ASH 2021 | Novel treatment strategies for Richter’s transformation
Jacqueline Barrientos
• 13 Dec 2021
Jacqueline Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, addresses Richter’s transformation, an aggressive form of chronic lymphocytic leukemia (CLL), as a current area of unmet medical need. Current treatments are inadequate in treating Richter’s transformation and various clinical trials are underway to improve patient outcomes. Novel therapies and regimens such as venetoclax with EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), and pirtobrutinib, a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, represent promising treatments for patients with Richter’s transformation. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
